- $171.94m
- $133.60m
- $322.02m
- 39
- 53
- 30
- 36
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 164 | 186 | 252 | 288 | 322 |
Cost of Revenue | |||||
Gross Profit | 113 | 128 | 178 | 192 | 214 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 201 | 233 | 314 | 378 | 394 |
Operating Profit | -36.8 | -46.6 | -62.4 | -89.5 | -71.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -38.2 | -47.8 | -63.1 | -92.2 | -71.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -38.2 | -47.9 | -63.2 | -92.3 | -71.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -38.2 | -47.9 | -63.2 | -92.3 | -71.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -38.2 | -47.7 | -63.2 | -92.3 | -71.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.42 | -0.525 | -0.819 | -0.925 | -0.679 |
Dividends per Share |